Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Literature DB >> 25589899

Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Abstract

Next-generation antisense technologies are re-emerging as viable and powerful approaches to the treatment of several genetic diseases. Similar strategies are also being applied to cancer therapy. Re-programming of the expression of endogenous oncogenic products to replace them with functional antagonists, by interfering with alternative splicing or polyadenylation, provides a promising novel approach to address acquired drug resistance and previously undruggable targets.

Entities: Chemical Disease Gene Mutation Species

Year: 2013 PMID： 25589899 PMCID： PMC4290377 DOI： 10.1016/j.ddstr.2013.06.002

Source DB: PubMed Journal: Drug Discov Today Ther Strateg ISSN： 1740-6773

87 in total

1. Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing.

Authors: Bin Tian; Zhenhua Pan; Ju Youn Lee
Journal: Genome Res Date: 2007-01-08 Impact factor: 9.043

2. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites.

Authors: Rickard Sandberg; Joel R Neilson; Arup Sarma; Phillip A Sharp; Christopher B Burge
Journal: Science Date: 2008-06-20 Impact factor: 47.728

3. The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements.

Authors: Pascaline Gaildrat; Sophie Krieger; Jean-Christophe Théry; Audrey Killian; Antoine Rousselin; Pascaline Berthet; Thierry Frébourg; Agnès Hardouin; Alexandra Martins; Mario Tosi
Journal: J Med Genet Date: 2010-06 Impact factor: 6.318

Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

1. Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing.

2. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites.

3. The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements.

Review 4. Targeted therapies: how personal should we go?

Review 5. Cell signaling by receptor tyrosine kinases.

6. Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells.

Review 7. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.

8. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Review 9. The molecular basis of β-thalassemia.

Review 10. Pick one, but be quick: 5' splice sites and the problems of too many choices.

Review 1. Alternative Splicing in the Hippo Pathway-Implications for Disease and Potential Therapeutic Targets.

Review 2. Alternative Pre-mRNA Splicing of the Mu Opioid Receptor Gene, OPRM1: Insight into Complex Mu Opioid Actions.

Review 3. U1 snRNP-Dependent Suppression of Polyadenylation: Physiological Role and Therapeutic Opportunities in Cancer.